BridgeBio Pharma (NASDAQ:BBIO) Issues Earnings Results, Beats Estimates By $0.12 EPS

BridgeBio Pharma (NASDAQ:BBIO) issued its quarterly earnings data on Thursday. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12, FiscalAI reports. The company had revenue of $353.17 million for the quarter, compared to the consensus estimate of $293.47 million. During the same quarter in the previous year, the company earned ($0.95) earnings per share. BridgeBio Pharma’s quarterly revenue was up 192.6% compared to the same quarter last year.

Here are the key takeaways from BridgeBio Pharma’s conference call:

• Attruby U.S. net product revenue rose 134% year over year to $253.2 million, up approximately 14% sequentially, with growth driven primarily by first-line new patient starts. Management expects near-term quarterly increases of roughly $25 million to $30 million and believes the franchise can meet or exceed its $4 billion peak-sales assumption.
• New real-world analyses continued to favor acoramidis over tafamidis, including an 18% lower composite risk in an independent 2,684-patient EHR analysis and 25%-27% lower hospitalization risks. Management said the findings, along with kidney-function and longer-term survival data, are strengthening Attruby’s commercial differentiation.
• BridgeBio highlighted three potential launches within the next seven months: BBP-418 has a November 27, 2026 PDUFA date, infigratinib has a February 4, 2027 date, and encaleret has a May 8, 2027 date. The company said launch teams are deployed, BBP-418 manufacturing is ready, and it expects traditional approval for BBP-418.
• Third-quarter total revenue increased to $353.2 million from $120.7 million, helped by Attruby growth, $20.5 million in royalties, and a one-time $75 million Bayer milestone. Cash and marketable securities reached a record $1.5 billion, which management believes is sufficient to fund operations and the upcoming launches while operating losses improve toward potential profitability across the portfolio by 2028.
• Management emphasized that significant opportunities remain, including more than 60% of U.S. prescribers who have not yet tried Attruby and a potential expansion of encaleret into chronic hypoparathyroidism, a market estimated at roughly 200,000 patients in the U.S. and Europe. However, European filing for BBP-418 is now planned for the first half of 2028 because regulators requested 36-month data, delaying that opportunity relative to the U.S.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $74.95 on Friday. BridgeBio Pharma has a one year low of $60.22 and a one year high of $93.42. The stock’s fifty day moving average is $70.27 and its 200-day moving average is $72.84.

Analysts Set New Price Targets

BBIO has been the subject of several analyst reports. Barclays reduced their price target on shares of BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. TD Cowen cut their price objective on shares of BridgeBio Pharma from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday. Canaccord Genuity Group lifted their price objective on shares of BridgeBio Pharma from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Morgan Stanley boosted their target price on shares of BridgeBio Pharma from $87.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Mizuho upped their target price on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 1st. Nineteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $104.16.

Trending Headlines about BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Q3 performance: BridgeBio reported third-quarter revenue of $353.2 million, well above the $293.5 million consensus estimate. The company’s loss of $0.42 per share was also narrower than expectations for a $0.54 loss and improved substantially from a $0.95 loss a year earlier. BridgeBio Pharma Q3 earnings report
• Positive Sentiment: Attruby sales accelerated: U.S. Attruby net product revenue reached $253.2 million, increasing approximately $31 million sequentially and $145 million year over year. Revenue also benefited from a one-time $75 million BEYONTTRA sales milestone from Bayer. BridgeBio third-quarter financial results
• Positive Sentiment: Solid financial flexibility: BridgeBio ended September with $1.5 billion in cash, cash equivalents and marketable securities, which management said fully funds all three launches and expansion indications. BridgeBio corporate update
• Positive Sentiment: Morgan Stanley raised its target: The firm increased its price target from $87 to $88 and maintained an “overweight” rating, signaling continued confidence in BBIO’s outlook. Morgan Stanley recommendations
• Negative Sentiment: TD Cowen reduced its target: Although the firm maintained a “buy” rating and still sees substantial upside, it lowered its price target from $110 to $100, tempering the overall analyst optimism. TD Cowen recommendations

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the sale, the chief executive officer directly owned 495,686 shares in the company, valued at approximately $34,241,988.88. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 54,980 shares of company stock valued at $4,417,999. 14.23% of the stock is currently owned by insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.